Capacity
toCure
At Poseida Therapeutics, we are boldly developing new solutions to redefine treatment paradigms for life-threatening cancers and genetic diseases. We have designed our genetic engineering technologies to represent the future of innovation in cell and gene therapies, giving new hope to patients.
At Poseida Therapeutics, we are boldly developing new solutions to redefine treatment paradigms for life-threatening cancers and genetic diseases. We have designed our genetic engineering technologies to represent the future of innovation in cell and gene therapies, giving new hope to patients.
TECHNOLOGY
A Suite of Differentiated Genetic Engineering Platforms
Our non-viral piggyBac® DNA Delivery System inserts large genetic payloads into the genome. Our Cas-CLOVER™ Site-Specific Gene Editing System can be leveraged to make accurate site-specific deletions, insertions, and knock-ins in multiple cell types.
PIPELINE
Cell Type Matters
Our gene editing technologies and delivery platforms allow us to target many different cell types to treat cancer and genetic diseases. By focusing on specific cell populations, we can potentially advance fully allogeneic CAR-T therapies with an early memory phenotype for patients fighting cancer or develop functional cures for rare genetic diseases.
ABOUT US
Poseida Stands Apart
Our leadership team combines long-standing scientific expertise with the strategic insight needed to advance the company forward and deliver novel therapeutics for patients.
Latest News and Updates
Poseida Therapeutics Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting
December 10, 2023
Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2023
November 9, 2023
Poseida Therapeutics to Present at the 65th ASH Annual Meeting and Exposition
November 2, 2023